Mucolipidosis II Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 | Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Indus

As per the report, the mucolipidosis II market size has grown steadily in recent years. It will grow from $12.61 billion in 2023 to $13.13 billion in 2024 at a compound annual growth rate (CAGR) of 4.1%. The mucolipidosis II market size is expected to see steady growth in the next few years. It will grow to $15.52 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16746&type=smp

Gene Therapy Advancements Propel Growth of the Mucolipidosis II Market
The rise in gene therapy is expected to propel the growth of the mucolipidosis II market going forward. Gene therapy is an advanced medical technique that aims to treat or prevent genetic disorders by correcting faulty genes or introducing new genes into a patient's cells through methods such as gene addition, gene editing, gene silencing, and gene regulation, gene therapy. Gene therapy offers a promising approach to treating ML II by addressing the root genetic cause of the disorder. The approach involves introducing a functional copy of the gene into the patient's cells to restore the production of the enzyme. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in phase III clinical trials increased by 10% in the third quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Therefore, the rise in gene therapy will drive the market for mucolipidosis II.

Impact of Increased Research and Development Activities on the Mucolipidosis II Market

The rise in research and development activities is expected to propel the growth of the mucolipidosis II market going forward. Research and development (R&D) activities involve systematic investigation and experimentation to discover new knowledge or create new products, processes, or services. Research and development (R&D) activities are increasing due to the growing need for innovation and competitive advantage in various industries. Research and development activities are crucial for advancing treatments for Mucolipidosis II by improving the understanding of the disease, developing gene therapies to address underlying genetic mutations, enhancing delivery methods, and conducting preclinical and clinical trials. For instance, in April 2024, according to the Office for National Statistics, a UK-based government department for collecting and publishing statistics, in 2022, the UK government's spending on research and development increased to £15.5 ($19.67) billion from £14.0 ($17.77) billion in 2021, marking a 10.5% rise. Therefore, the rise in research and development activities will drive the market for mucolipidosis II.

Advances in Gene Therapy for Mucolipidosis II
Major companies operating in the mucolipidosis II market are developing gene therapies to address the underlying genetic mutations causing the disease. Gene therapies aim to deliver functional copies of the defective genes into patients' cells, thereby correcting the metabolic dysfunctions characteristic of ML II. For instance, in February 2021, M6P Therapeutics, a US-based biotechnology company, received orphan drug designation for M002 S1S3 PTase AAV gene therapy for mucolipidosis. It leverages M6P Therapeutics' S1S3 bicistronic platform to deliver a truncated phosphotransferase (PTase) enzyme via an AAV-9 vector. In the ML-II mouse model, M002 restores phosphorylation of soluble lysosomal enzymes within transduced cells within 3 weeks after dosing.

The mucolipidosis ii market covered in this report is segmented -

1) By Treatment: Antibiotics, Physical Therapy, Hip Replacement, Experimental Therapies, Other Treatments
2) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration
3) By Symptoms: Deafness, Lack Of Muscle Tone (Hypotonia), Abnormal Spine Curvature, Changing Proportion of Mental Retardation, Low Growth Of Gross And Fine Motor Skills, Other Symptoms
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16746&type=discount

Major companies operating in the mucolipidosis ii market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alembic Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Regenxbio Inc., Denali Therapeutics Inc., Mylan N.V., Intellia Therapeutics Inc., Avrobio Inc., Orchard Therapeutics plc, Eloxx Pharmaceuticals Inc., Lysogene S.A., Sio Gene Therapies, Homology Medicines Inc., BSN medical GmbH, Abeona Therapeutics Inc

Contents of the report:
1. Executive Summary
2. Mucolipidosis II Market Report Structure
3. Mucolipidosis II Market Trends And Strategies
4. Mucolipidosis II Market - Macro Economic Scenario
5. Mucolipidosis II Market Size And Growth
…..
27. Mucolipidosis II Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/mucolipidosis-ii-global-market-report

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.